Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2006
Business Overview: Teva is a global pharmaceutical company and the leading generic drug manufacturer in the world and the United States. Its business model combines generic drugs, branded generics, innovative proprietary products (notably Copaxone® for multiple sclerosis and Azilect® for Parkinson's disease), specialty pharmaceuticals (respiratory), and Active Pharmaceutical Ingredients (API).
Key Event: The 2006 results include the consolidation of Ivax Corporation, acquired in January 2006 for approximately $7.9 billion, significantly expanding Teva's presence in the U.S., Western Europe, Latin America, and Central/Eastern Europe.
Key Financial Metrics
| Metric (in millions USD) | 2006 | 2005 |
|---|---|---|
| Net Sales | $8,408 | $5,250 |
| Gross Profit | $4,259 | $2,480 |
| Gross Margin | 50.7% | 47.2% |
| Operating Income | $801 | $1,312 |
| Net Income (GAAP) | $546 | $1,072 |
| Diluted EPS | $0.69 | $1.59 |
| Working Capital | $3,569 | $3,245 |
| Total Debt (Short + Long Term) | $5,327 | $2,148 |
| Free Cash Flow | $1,463 | $901 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 60% to $8.4 billion, driven primarily by the Ivax acquisition and major U.S. generic launches with market exclusivity (Zocor, Zoloft, Wellbutrin XL, Pravachol).
- Profitability Decline: GAAP Net Income decreased 49% to $546 million. This decline is largely due to non-cash charges totaling approximately $1.39 billion, including a $1.295 billion write-off of in-process research and development (IPR&D) related to the Ivax acquisition, a $95 million inventory step-up, and litigation settlement costs.
- Adjusted Performance: Management reports "As Adjusted" Net Income of $1.867 billion (EPS $2.30), excluding acquisition-related charges, reflecting a 74% increase in underlying operational profitability compared to 2005.
- Debt Increase: Total debt increased significantly to finance the Ivax acquisition, with new issuances of $2.9 billion in senior notes and convertible debentures.
- Expense Increases: SG&A expenses rose 97% and R&D expenses rose 34%, reflecting the inclusion of Ivax's operations and increased spending on innovative pipelines (Copaxone and Azilect).
Guidance, Outlook, and Risks
Outlook and Commentary:
- Product Pipeline: Teva anticipates substantial new product launches in 2007, though none are expected to match the concentration of large exclusivity launches seen in 2006. The company expects 2008 to include substantial launches again.
- Copaxone®: Global sales reached a record $1.414 billion (+20%). Teva will assume full distribution responsibility in the U.S. and Canada in April 2008, increasing reported revenue but also SG&A expenses.
- Respiratory Business: Acquired via Ivax, this franchise generated approximately $500 million in sales in 2006 and is expected to benefit from the phase-out of CFC-based inhalers.
Key Risks and Contingencies:
- Patent Litigation: Teva faces ongoing patent litigation regarding products like Allegra, Wellbutrin XL, and Neurontin. While settlements have been reached for some (e.g., Pfizer), adverse rulings could result in significant damages or injunctions.
- Regulatory Environment: Changes in U.S. Medicare Part D, Medicaid reimbursement rates, and European pricing regulations pose risks to margins and sales volumes.
- Competition: Intense competition from brand-name companies (via authorized generics) and other generic manufacturers continues to pressure prices and margins.
- Geopolitical: Significant operations in Israel expose the company to risks related to regional instability and acts of terrorism.
Investor Verification Checklist
- Adjusted vs. GAAP Earnings: Verify the magnitude of the $1.3 billion+ non-GAAP adjustments (IPR&D write-offs, inventory step-up) to understand the true operational performance versus reported GAAP results.
- Debt Service Capacity: Assess the impact of the new $2.9 billion debt issuance on future interest expenses and liquidity, given the increased financial costs ($95 million in 2006).
- Exclusivity Pipeline: Confirm the status of pending Paragraph IV challenges and the expected launch dates for 2007/2008 exclusivity products, as these drive future revenue growth.
- Patent Litigation Exposure: Review the status of pending lawsuits (e.g., Allegra, Wellbutrin XL) to evaluate potential future liabilities or sales interruptions.
- Copaxone® Transition: Monitor the financial impact of taking over full distribution of Copaxone® in 2008, specifically the net effect of increased revenue versus increased SG&A.